The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Brilliant Yu.M.

Institute for Medical Cell Technologies, Ministry of Health of the Sverdlovsk Region, Yekaterinburg, Russia;
Ural State Medical University, Ministry of Health of Russia, Yekaterinburg, Russia

Brilliant A.A.

Institute of Medical Cell Technologies

Sazonov S.V.

GBUZ SO "Institut meditsinskikh kletochnykh tekhnologiĭ", Ekaterinburg

Epithelial cadherins and associated molecules in invasive lobular breast cancer

Authors:

Brilliant Yu.M., Brilliant A.A., Sazonov S.V.

More about the authors

Read: 4246 times


To cite this article:

Brilliant YuM, Brilliant AA, Sazonov SV. Epithelial cadherins and associated molecules in invasive lobular breast cancer. Russian Journal of Archive of Pathology. 2017;79(1):12‑18. (In Russ.)
https://doi.org/10.17116/patol201779112-18

Recommended articles:

References:

  1. Halbleib JM, Nelson JM. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 2006;20(23):3199-3214. doi:10.1101/gad.1486806
  2. Zasadkevich Yu, Sazonov S, Brilliant A. Role of cadherins in health and in developing breast cancer. Arkhiv patologii. 2015;77(3):57-64. (In Russ.) doi:10.17116/patol201577357-64
  3. Kotb AM, Hierholzer A, Kemler R. Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation. Breast Cancer Res. 2011;13:R104. doi:10.1186/bcr3046
  4. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602. doi:10.1038/nrc1670
  5. Frank G, Zavalishina L, Andreeva Yu. Status of extracellular matrix and adhesion markers in urothelial cancer of the urinary bladder. Arkhiv patologii. 2005;67(3):11-14. (In Russ.)
  6. Cowin P, Rowlands W, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005;17(5):499-508. doi:10.1016/j.ceb.2005.08.014
  7. Qureshi HS, Linden MD, Divine G, Raju UB. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol. 2006;125(3):377-385. doi:10.1309/wmx7drwtfvqp2lqt
  8. Shi Y, Liu X, Sun Y, Wu D, Qiu A, Cheng H, Wu C, Wang X. Decreased expression and prognostic role of EHD2 in human breast carcinoma: correlation with E-cadherin. J Mol Histol. 2015;46(2):221-231. doi:10.1007/s10735-015-9614-7
  9. Frank G, Zavalishina L, Pozharisskii K, eds. Breast cancer. A practical guide for doctors [Rak molochnoi zhelezy. Prakticheckoe rukovodstvo dlya vrachei]. Moscow: Prakticheskaya meditsina; 2014. (In Russ.)
  10. Brilliant AA, Sazonov SV, Zasadkevich YM. Chapter 21. Modification of receptor status in groups of proliferative activity of breast carcinomas. In: Joswik R, Zaikov GE, Haghi AK, eds. Life chemistry research. Biological Systems. Apple Academic Press; 2015:247-255. doi:10.1201/b18527-25
  11. Semiglazov V, Paltuev R. Semiglazova T, et al. Clinical recommendations at breast cancer diagnostics and treatment [Klinicheskie rekomendatsii po diagnostike i lecheniyu raka molochnoi zhelezy]. St. Petersburg: ABV-press; 2013. (In Russ.)
  12. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 Index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-750. doi:10.1093/jnci/djp082
  13. Kowalski PG, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 2003;5:R217. doi:10.1186/bcr651
  14. Vieira AF, Ricardo S, Ablett MP, Dionísio MR, Mendes N, Albergaria A, et al P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in Basal-like breast cancer. Stem cells. 2012;30(5):854-864. doi:10.1002/stem.1075
  15. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta. 2012;1826(2):297-311. doi:10.1016/j.bbcan.2012.05.002
  16. Ng TL, Gown AM, Barry TS, Cheang MCU, Chan AKW, Turbin DA, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68-74. doi:10.1038/modpathol.3800272
  17. Ikeda S, Fujimori M, Shibata S, Okajima M, Ishizaki Y, Kurihara T, et al. Combined immunochemistry of β-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006;6(31). doi:10.1186/1471-2407-6-31
  18. Liu Y, Wang Y, Zhang Y, Miao Y, Zhao Y, Zhang PX, et al. Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer. Lung Cancer. 2009;63(3):375-382. doi:10.1016/j.lungcan.2008.12.012
  19. Sarrió D, Pérez-Mies B, Hardisson D, Moreno-Bueno G, Suárez A, Cano A, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene. 2004;23:3272-3283. doi:10.1038/sj.onc.1207439
  20. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wülfing P, van Diest PJ, et al. The origin of vimentin expression in invasive breast cancer: epithelial—mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol. 2005;206(4):451-457. doi:10.1002/path.1797
  21. Hammond MEH, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195-197. doi:10.1200/JOP.777003
  22. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16(2):173-182.
  23. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984
  24. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006;48(6):674-682. doi:10.1111/j.1365-2559.2006.02402.x
  25. Zar JH. Biostatistical analysis. 5th ed. Prentice-Hall/Pearson; 2010.
  26. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96(12):926-935. doi:10.1093/jnci/djh166
  27. Ribeiro AS, Sousa B, Carreto B, Mendes N, Nobre AR, Ricardo S, et al. P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol. 2013;229(5):705-718. doi:10.1002/path.4143
  28. Lee JM., Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973-981. doi:10.1083/jcb.200601018

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.